In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives.

We describe the synthesis and characterization of two acetazolamide derivatives containing either a charged fluorophore or an albumin-binding moiety, which restrict binding to carbonic anhydrase IX and XII present on tumor cells. In vivo studies showed the preferentially targeting of tumor cells by the fluorescent acetazolamide derivative and the ability of the albumin-binding acetazolamide derivative to cause tumor retardation in a SK-RC-52 xenograft model of cancer.

[1]  Roy Bicknell,et al.  Tumour vascular targeting , 2005, Nature Reviews Cancer.

[2]  J. Lennerz,et al.  Neuropathology for the neuroradiologist: palisades and pseudopalisades. , 2006, AJNR. American journal of neuroradiology.

[3]  J. Folkman.  Angiogenesis in cancer, vascular, rheumatoid and other disease , 1995, Nature Medicine.

[4]  P. Lambin,et al.  Imaging the hypoxia surrogate marker CA IX requires expression and catalytic activity for binding fluorescent sulfonamide inhibitors. , 2007, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[5]  Min Zhang,et al.  Albumin Binding as a General Strategy for Improving the Pharmacokinetics of Proteins* , 2002, The Journal of Biological Chemistry.

[6]  L. Zardi,et al.  Extracellular pH controls pre‐mRNA alternative splicing of tenascin‐C in normal, but not in malignantly transformed, cells , 1996, International journal of cancer.

[7]  P. Cuq,et al.  Combination of thymidine phosphorylase gene transfer and deoxyinosine treatment greatly enhances 5-fluorouracil antitumor activity in vitro and in vivo. , 2001, Molecular cancer therapeutics.

[8]  D. Rea,et al.  Hypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer , 2007, British Journal of Cancer.

[9]  Christof Baltes,et al.  A portable albumin binder from a DNA-encoded chemical library. , 2008, Angewandte Chemie.

[10]  J. Pouysségur,et al.  Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. , 2009, Cancer research.

[11]  C. Supuran,et al.  Carbonic anhydrase inhibitors: Hypoxia-activatable sulfonamides incorporating disulfide bonds that target the tumor-associated isoform IX. , 2006, Journal of medicinal chemistry.

[12]  J. Folkman,et al.  Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.

[13]  G. Winter,et al.  Making antibodies by phage display technology. , 1994, Annual review of immunology.

[14]  D. Goldenberg,et al.  Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts. , 1994, Cancer research.

[15]  H. Moch,et al.  Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL , 2003, Nature.

[16]  L. Zardi,et al.  The Alternative Splicing Pattern of the Tenascin-C Pre-mRNA Is Controlled by the Extracellular pH (*) , 1995, The Journal of Biological Chemistry.

[17]  C. Supuran,et al.  Hypoxia activates the capacity of tumor‐associated carbonic anhydrase IX to acidify extracellular pH , 2004, FEBS letters.

[18]  P. Ratcliffe,et al.  The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. , 2003, Seminars in cancer biology.

[19]  S. Ross,et al.  Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent. , 2007, Cancer research.

[20]  P. Carter,et al.  Antibody-Drug Conjugates for Cancer Therapy , 2008, Cancer journal.

[21]  J. Pastorek,et al.  Immunotargeting of human cervical carcinoma xenograft expressing CA IX tumor-associated antigen by 125I-labeled M75 monoclonal antibody. , 2003, Neoplasma.

[22]  Claudiu T. Supuran,et al.  Carbonic anhydrases: novel therapeutic applications for inhibitors and activators , 2008, Nature Reviews Drug Discovery.

[23]  Y. Pocker,et al.  The catalytic versatility of erythrocyte carbonic anhydrase. 3. Kinetic studies of the enzyme-catalyzed hydrolysis of p-nitrophenyl acetate. , 1967, Biochemistry.

[24]  G. Fleuren,et al.  Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal‐cell carcinoma xenografts: Relative effects of size and affinity , 1991, International journal of cancer.

[25]  D. Neri,et al.  Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: A transcriptomic and proteomic study , 2004, Proteomics.

[26]  P H Watson,et al.  Hypoxia-inducible expression of tumor-associated carbonic anhydrases. , 2000, Cancer research.

[27]  J. Pouysségur,et al.  Hypoxia and cancer , 2007, Journal of Molecular Medicine.

[28]  J. Pastorek,et al.  Biodistribution and pharmacokinetics of 125I‐labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma , 2003, International journal of cancer.

[29]  W. Oyen,et al.  Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  Philip S Low,et al.  Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. , 2008, Accounts of chemical research.

[31]  W. Oyen,et al.  Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[32]  R. Chari,et al.  Targeted cancer therapy: conferring specificity to cytotoxic drugs. , 2008, Accounts of chemical research.

[33]  C. Supuran,et al.  Carbonic anhydrase inhibitors. Design of fluorescent sulfonamides as probes of tumor-associated carbonic anhydrase IX that inhibit isozyme IX-mediated acidification of hypoxic tumors. , 2005, Journal of medicinal chemistry.